Extra J&J troubles: Vaccine manufacturing halted and extra doable clot circumstances

The Emergent BioSolutions plant, a manufacturing partner for Johnson & Johnson's Covid-19 vaccine, in Baltimore, Maryland, on April 9, 2021.

Enlarge / The Emergent BioSolutions plant, a producing associate for Johnson & Johnson’s Covid-19 vaccine, in Baltimore, Maryland, on April 9, 2021. (credit score: Getty | Saul Loeb)

The US Meals and Drug Administration final week requested Emergent BioSolutions to cease making Johnson & Johnson’s COVID-19 vaccine at its troubled facility in Baltimore, in response to a regulatory submitting Emergent launched Monday.

The FDA had begun an inspection of the contract producer’s facility on April 12 however requested on April 16 that manufacturing be halted “pending completion of the inspection and remediation of any ensuing findings,” the submitting reads. Any vaccine supplies already made on the plant shall be held in quarantine.

The manufacturing halt follows information final month {that a} mishap on the plant led to the spoil of 15 million doses of Johnson & Johnson’s one-shot COVID-19 vaccine. The ruined doses had reportedly been contaminated with substances from AstraZeneca’s COVID-19 vaccine, which was additionally being manufactured on the plant on the time.

Learn 10 remaining paragraphs | Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *